



HEALTH CARE SPOTLIGHT: 4th QUARTER 2011 OVERVIEW

PUBLIC STOCK PERFORMANCE



HEALTH CARE RECAP:

4Q:11 Recap:

- The M&A market in Q4:11 generated 247 deals worth a combined total of \$40.2 billion. This represents a 6% gain over the 234 deals from the previous quarter, but a 12% drop from the 282 deals recorded in the year-ago quarter, Q4:10.
- Health care services accounted for the majority of deal volume in the quarter with 139 deals posted, while health care technology captured 69% of the quarter's total dollar volume.
- 3% of the deals accounted for 65% of all health care M&A dollars spent in the quarter, with eight deals worth a combined total of \$26.2 billion.

2011 Recap



- In 2011 980 deals were announced worth a total of \$227.4 billion, which consisted of 545 health care service deals (56% of the total deal volume) and the remaining 435 deals were in health care technology.
- As in Q4, while health care technology (including medical devices) lagged in deal volume, it captured \$146.7 billion or 65% of the total dollar volume for 2011.
- Financial buyers announced a total of 67 deals in 2011, accounting for 15% of the market's total deal volume; they paid \$34.5 billion for their acquisitions.

Looking into 2012

- 2012 is expected to develop similar themes to 2011, with continued strength in Medical Device M&A as new technologies spur product innovation.
- One major factor that could spoil the health care M&A environment is the 2012 election. An administration run by President Obama would look to continue to reform health care, while a Republican administration would look to reverse portions of The Patient Protection and Affordable Care Act of 2010.

Source: Irving Levin Associates, Inc. *Health Care M&A Monthly*


MEAN PUBLIC VALUATION MULTIPLES




Source: Capital IQ and Company Documents

HEALTH CARE M&A HISTORICAL DATA

Historical Health Care Transactions Volume



4th Quarter Health Care M&A Activity



MAJOR MERGER & ACQUISITION TRANSACTIONS OF THE 4th QUARTER

Announced Date	Target	Total Transaction Value (\$mm)	Buyer	Target Business Description
Dec-11	Enobia Pharma Corp.	1,080	Alexion Pharmaceuticals, Inc.	Clinical-stage biotech company in Quebec.
Dec-11	ISTA Pharmaceuticals, Inc.	327	Valeant Pharmaceuticals	Pharmaceutical company that develops and markets eye remedies in CA.
Dec-11	Intellikine, Inc.	310	Takeda Pharmaceutical Co. Ltd.	Pharmaceutical company that develops drugs in CA.
Nov-11	Pharmasset, Inc.	11,000	Gilead Sciences, Inc.	A clinical-stage biopharmaceutical company in NJ.
Nov-11	Psychiatric drug alliance	2,000	H. Lundbeck A/S	Developer and seller of psychiatric and neuroscience drugs in Japan.
Nov-11	Physio-Control	487	Bain Capital Partners, LLC	Provider of emergency medical response technology in WA.
Oct-11	Atrium Medical Corp.	680	Getinge AB	Provider of medical devices in NH.
Oct-11	Adolor Corp.	415	Cubist Pharmaceuticals, Inc.	Discovers, develops and commercializes prescription pain products in PA.
Oct-11	Skilled nursing portfolio	167	Grubb & Ellis Healthcare REIT	1,364-bed skilled nursing facilities in AL, GA, LA, and TN.

Source: Irving Levin Associates, Inc. *Health Care M&A Monthly*

HEALTH CARE CONTACT INFORMATION

Leslie Feldman

Managing Director

leslie.feldman@eurekacap.com

Ph: 646.277.8423

Mark O'Keefe

Managing Director

mark.okeefe@eurekacap.com

ph: 949.719.2263

EUREKA CAPITAL MARKETS, LLC, MEMBER FINRA/SIPC

Eureka Capital is an independent financial advisory firm with offices in New York and California. Our firm was established to provide companies with impartial, thoughtful and sophisticated advice for mergers, acquisitions, financial restructurings, ESOP buyouts, valuations, fairness opinions, and capital raising. Eureka also initiates merchant banking transactions by making principal investments in select transactions and partnering with industry executives to identify and purchase operating companies. Collectively, we have completed more than 400 domestic and cross-border transactions during our careers. We are not a volume-based business. At Eureka, we are committed to providing value-added advice to a select group of clients on businesses we understand.

New York

286 Madison Ave., Suite 1300

New York, NY 10017

Ph: 646.277.8420

Fx: 646.277.8421

California

23 Corporate Plaza, Suite 125

Newport Beach, CA 92660

Ph: 949.719.2260

Fx: 949.719.2314

This report is for information purposes only and is not intended as an offer or solicitation with respect to any purchase or sale of any security. Eureka Capital Markets, LLC gathers its data from sources it considers reliable; however, it does not guarantee the accuracy or completeness of the information provided within this publication. The opinions presented herein reflect the current judgment of the authors and are subject to change. Eureka Capital Markets, LLC makes no warranties, expressed or implied, regarding the accuracy of this information or the subjective opinions expressed by the authors. Eureka Capital Markets, LLC, its officers, directors and partners may at any time have positions in the securities of the companies discussed herein.